178 related articles for article (PubMed ID: 19854050)
1. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Su B; Chen S
Bioorg Med Chem Lett; 2009 Dec; 19(23):6733-5. PubMed ID: 19854050
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
Su B; Cai X; Hong Y; Chen S
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):232-8. PubMed ID: 20542113
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells.
Zhong B; Cai X; Yi X; Zhou A; Chen S; Su B
J Steroid Biochem Mol Biol; 2011 Aug; 126(1-2):10-8. PubMed ID: 21458568
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76.
Zhong B; Lama R; Smith KM; Xu Y; Su B
Bioorg Med Chem Lett; 2011 Sep; 21(18):5324-7. PubMed ID: 21807508
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Su B; Landini S; Davis DD; Brueggemeier RW
J Med Chem; 2007 Apr; 50(7):1635-44. PubMed ID: 17315855
[TBL] [Abstract][Full Text] [Related]
6. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Su B; Tian R; Darby MV; Brueggemeier RW
J Med Chem; 2008 Mar; 51(5):1126-35. PubMed ID: 18271519
[TBL] [Abstract][Full Text] [Related]
7. Nimesulide analogues: From anti-inflammatory to antitumor agents.
Catarro M; Serrano JL; Ramos SS; Silvestre S; Almeida P
Bioorg Chem; 2019 Jul; 88():102966. PubMed ID: 31075744
[TBL] [Abstract][Full Text] [Related]
8. New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.
Güngör T; Ozleyen A; Yılmaz YB; Siyah P; Ay M; Durdağı S; Tumer TB
Eur J Med Chem; 2021 Oct; 221():113566. PubMed ID: 34077833
[TBL] [Abstract][Full Text] [Related]
9. Selective regulation of aromatase expression for drug discovery.
Brueggemeier RW; Su B; Darby MV; Sugimoto Y
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):207-10. PubMed ID: 19931613
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.
Su B; Darby MV; Brueggemeier RW
J Comb Chem; 2008; 10(3):475-83. PubMed ID: 18380483
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
Lu X; Zhang H; Li X; Chen G; Li QS; Luo Y; Ruan BF; Chen XW; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(22):6827-32. PubMed ID: 22000948
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Hybrids of Dihydropyrimidine and Pyridazinone as potential Anti-Breast Cancer Agents.
Akhtar W; Verma G; Khan MF; Shaquiquzzaman M; Rana A; Anwer T; Akhter M; Alam MM
Mini Rev Med Chem; 2018; 18(4):369-379. PubMed ID: 28486908
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.
Di Matteo M; Ammazzalorso A; Andreoli F; Caffa I; De Filippis B; Fantacuzzi M; Giampietro L; Maccallini C; Nencioni A; Parenti MD; Soncini D; Del Rio A; Amoroso R
Bioorg Med Chem Lett; 2016 Jul; 26(13):3192-3194. PubMed ID: 27161804
[TBL] [Abstract][Full Text] [Related]
14. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
Su B; Diaz-Cruz ES; Landini S; Brueggemeier RW
J Med Chem; 2006 Feb; 49(4):1413-9. PubMed ID: 16480277
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates.
Zhang B; Hu XT; Gu J; Yang YS; Duan YT; Zhu HL
Bioorg Chem; 2020 Dec; 105():104390. PubMed ID: 33137555
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer.
Kalalinia F; Jouya M; Komachali AK; Aboutourabzadeh SM; Karimi G; Behravan J; Abnous K; Etemad L; Kamali H; Hadizadeh F
Anticancer Agents Med Chem; 2018; 18(7):1016-1024. PubMed ID: 29336269
[TBL] [Abstract][Full Text] [Related]
17. From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Zhong B; Cai X; Chennamaneni S; Yi X; Liu L; Pink JJ; Dowlati A; Xu Y; Zhou A; Su B
Eur J Med Chem; 2012 Jan; 47(1):432-444. PubMed ID: 22119125
[TBL] [Abstract][Full Text] [Related]
18. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
19. New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study.
Maccallini C; Gallorini M; Sisto F; Akdemir A; Ammazzalorso A; De Filippis B; Fantacuzzi M; Giampietro L; Carradori S; Cataldi A; Amoroso R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1632-1645. PubMed ID: 34289751
[TBL] [Abstract][Full Text] [Related]
20. Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells.
Sengel-Turk CT; Hascicek C; Bakar F; Simsek E
AAPS PharmSciTech; 2017 Feb; 18(2):393-403. PubMed ID: 27007742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
